Jack Meehan
Stock Analyst at Barclays
(3.10)
# 1,159
Out of 4,840 analysts
135
Total ratings
70.73%
Success rate
21.1%
Average return
Main Sectors:
Stocks Rated by Jack Meehan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Labcorp Holdings | Maintains: Equal-Weight | $240 → $250 | $242.53 | +3.08% | 15 | Apr 30, 2025 | |
| A Agilent Technologies | Maintains: Underweight | $120 → $125 | $108.53 | +15.18% | 20 | Feb 28, 2024 | |
| WAT Waters | Maintains: Equal-Weight | $275 → $288 | $346.37 | -16.85% | 10 | Aug 3, 2023 | |
| AVTR Avantor | Initiates: Overweight | $33 | $12.69 | +160.05% | 3 | Mar 3, 2021 | |
| ILMN Illumina | Initiates: Underweight | $325 | $80.37 | +304.38% | 8 | Mar 3, 2021 | |
| INMD InMode | Maintains: Overweight | $18 → $19 | $14.24 | +33.47% | 3 | Aug 17, 2020 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $93 → $99 | $171.23 | -42.18% | 7 | Apr 23, 2020 | |
| ICLR ICON Public Limited Company | Maintains: Overweight | $170 → $180 | $127.99 | +40.64% | 2 | Apr 23, 2020 | |
| MYGN Myriad Genetics | Maintains: Underweight | $14 → $10 | $3.91 | +155.75% | 8 | Mar 26, 2020 | |
| IQV IQVIA Holdings | Maintains: Overweight | $192 → $166 | $137.00 | +21.17% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $43 | $54.28 | -20.78% | 9 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $154 | $136.73 | +12.63% | 7 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $223.78 | +92.15% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $234.55 | +83.33% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $29.74 | - | 10 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $52 → $48 | $35.50 | +35.21% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $720 → $680 | $1,114.14 | -38.97% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $30 | $110.82 | -72.93% | 3 | Oct 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $300 | $393.66 | -23.79% | 5 | Mar 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $40 | $1.55 | +2,480.65% | 1 | Dec 11, 2017 |
Labcorp Holdings
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $240 → $250
Current: $242.53
Upside: +3.08%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120 → $125
Current: $108.53
Upside: +15.18%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275 → $288
Current: $346.37
Upside: -16.85%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $12.69
Upside: +160.05%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $80.37
Upside: +304.38%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18 → $19
Current: $14.24
Upside: +33.47%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93 → $99
Current: $171.23
Upside: -42.18%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170 → $180
Current: $127.99
Upside: +40.64%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14 → $10
Current: $3.91
Upside: +155.75%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192 → $166
Current: $137.00
Upside: +21.17%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $51 → $43
Current: $54.28
Upside: -20.78%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $170 → $154
Current: $136.73
Upside: +12.63%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $223.78
Upside: +92.15%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $234.55
Upside: +83.33%
Mar 26, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $29.74
Upside: -
Mar 26, 2020
Upgrades: Overweight
Price Target: $52 → $48
Current: $35.50
Upside: +35.21%
Mar 26, 2020
Upgrades: Equal-Weight
Price Target: $720 → $680
Current: $1,114.14
Upside: -38.97%
Oct 2, 2019
Maintains: Underweight
Price Target: $28 → $30
Current: $110.82
Upside: -72.93%
Mar 18, 2019
Maintains: Overweight
Price Target: $295 → $300
Current: $393.66
Upside: -23.79%
Dec 11, 2017
Initiates: Equal-Weight
Price Target: $40
Current: $1.55
Upside: +2,480.65%